SCHEMBL6845384

SCHEMBL6845384

CCCCc1cccc(CO)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 2/20 0.53
LIPG Q9Y5X9 2/20 0.53
XIAP P98170 1/20 0.49
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SKP2 Q13309 1/20 0.44
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
ENPP2 Q13822 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44
GRIN3A Q8TCU5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7257290 0.94 LPL (0.61) LPLLIPGPPARGPPARA
SCHEMBL6272433 0.92 LPL (0.62) LPLLIPGPPARGPPARA
SCHEMBL347126 0.89 LPL (0.57) LPLLIPGXIAPNPC1HPGD
SCHEMBL8464457 0.88 CYP4F2 (0.54) LPLLIPGXIAPNPC1HPGD
SCHEMBL26240023 0.88 LPL (0.53) LPLLIPGXIAPNPC1HPGD
SCHEMBL6268248 0.87 ENPP2 (0.47) LPLLIPGENPP2GRIN2DGRIN3B
SCHEMBL10235637 0.86 LPL (0.56) LPLLIPGXIAPNPC1HPGD
SCHEMBL28141752 0.85 LPL (0.63) LPLLIPGXIAPPPARGPPARA
SCHEMBL28409443 0.85 LPL (0.53) LPLLIPGXIAPNPC1HPGD
SCHEMBL10235642 0.84 LPL (0.57) LPLLIPGXIAPPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190023641-A1 USE OF POLYMERIZATION INHIBITOR COMPOSITIONS SPECIALTY OPERATIONS FRANCE (FR) 2019-01-24 US claimed
US-12012475-B2 Method of olefin polymerization using alkane-soluble non-metallocene precatalyst DOW GLOBAL TECHNOLOGIES LLC (US) 2024-06-18 US disclosed
CN-112823163-B Alkane soluble non-metallocene precatalyst 陶氏环球技术有限责任公司 2024-04-19 CN disclosed
US-11859031-B2 Alkane-soluble non-metallocene precatalysts DOW GLOBAL TECHNOLOGIES LLC (US) 2024-01-02 US disclosed
EP-3877392-B1 ALKANE-SOLUBLE NON-METALLOCENE PRECATALYSTS DOW GLOBAL TECHNOLOGIES LLC (US) 2023-11-15 EP disclosed
CN-112839966-B Process for the polymerization of olefins using an alkane soluble non-metallocene pre-catalyst 陶氏环球技术有限责任公司 2023-07-28 CN disclosed
US-20230002373-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 US disclosed
US-20220010045-A1 ALKANE-SOLUBLE NON-METALLOCENE PRECATALYSTS DOW GLOBAL TECHNOLOGIES LLC 2022-01-13 US disclosed
US-20210403615-A1 METHOD OF OLEFIN POLYMERIZATION USING ALKANE-SOLUBLE NON-METALLOCENE PRECATALYST DOW GLOBAL TECHNOLOGIES LLC 2021-12-30 US disclosed
EP-3247677-B1 LIQUID ORGANIC COMPOSITION FOR ION EXTRACTION IN LIQUID PHASE ADIONICS (FR) 2021-12-08 EP disclosed
US-20040011638-A1 Adding at least one stabilizer of acrylic monomers; injecting oxygen into the distillation column; adding a metal sequestrant for stabilizing acrylic monomers in a distillation column ATOFINA (FR) 2004-01-22 US disclosed
US-6476021-B1 Compounds having cGMP-PDE inhibitory effect MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-11-05 US disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed
US-5149884-A Oxidative dehydrogenation of aromatic or aliphatic alcohols in gas phase BASF AKTIENGESELLSCHAFT (DE) 1992-09-22 US disclosed
EP-0278284-B1 PULVERULENT WATER-DISPERSIBLE CAROTENOID COMPOUNDS AND PROCESS TO PREPARE THEM BASF Aktiengesellschaft (DE) 1991-05-22 EP disclosed
EP-0244632-B1 TUBE BUNDLE REACTOR, ITS USE IN EXOTHERMAL ORGANIC REACTIONS AND PROCESS FOR THE PREPARATION OF KETONES AND ALDEHYDES BASF Aktiengesellschaft (DE) 1991-02-20 EP disclosed
EP-0278284-A1 Pulverulent water-dispersible carotenoid compounds and process to prepare them BASF Aktiengesellschaft (DE) 1988-08-17 EP disclosed
EP-0004881-B1 PROCESS FOR THE PREPARATION OF AROMATIC AND ARALIPHATIC ALDEHYDES BASF Aktiengesellschaft (DE) 1981-10-07 EP disclosed
US-4224254-A OXIDATION OF AROMATIC ALCOHOLS, SILVER CATALYST BASF AKTIENGESELLSCHAFT (DE) 1980-09-23 US disclosed
EP-0004881-A2 Process for the preparation of aromatic and araliphatic aldehydes BASF Aktiengesellschaft (DE) 1979-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11859031-B2 Alkane-soluble non-metallocene precatalysts AP1M1, CCNA1, AMY1A LPL 2459/4885LIPG 4106/4885XIAP 4798/4885
US-20230002373-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 LPL 1616/4885LIPG 164/4885XIAP 183/4885
US-20220010045-A1 ALKANE-SOLUBLE NON-METALLOCENE PRECATALYSTS AP1M1, CCNA1, AMY1A LPL 2459/4885LIPG 4106/4885XIAP 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.